Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.63 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.63 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.63 |
| ▸ | AMD1 | P17707 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21377709 | 1.00 | PI4KA (0.70) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL30546911 | 1.00 | PI4KA (0.70) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL24146635 | 1.00 | PI4KA (0.70) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13309395 | 0.90 | P2RX3 (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1795275 | 0.89 | RXFP1 (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1795964 | 0.89 | RXFP1 (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1795283 | 0.89 | RXFP1 (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL1795966 | 0.89 | RXFP1 (0.54) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL14429043 | 0.87 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9620170 | 0.87 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-16 | — | — | US | disclosed |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3645020-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | Memorial Sloan-Kettering Cancer Center (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3645561-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | Memorial Sloan-Kettering Cancer Center (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10301348-B2 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | ACADEMIA SINICA (TW) | 2019-05-28 | — | — | US | disclosed |
| WO-2019006465-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006467-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3060566-B1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20160264613-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ACADEMIA SINICA (TW) | 2016-09-15 | — | — | US | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PI4KA 2914/4885PI4K2B 3149/4885PI4K2A 3334/4885 |
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | PI4KA 1069/4885PI4K2B 1181/4885PI4K2A 1533/4885 |
| US-20160264613-A1 | COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN | ADORA2A, ADORA3, ADORA2B | PI4KA 3311/4885PI4K2B 3941/4885PI4K2A 2856/4885 |
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CCRL2, CCR3, LY6K | PI4KA 1274/4885PI4K2B 1278/4885PI4K2A 1414/4885 |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | PI4KA 1808/4885PI4K2B 2394/4885PI4K2A 2268/4885 |
| US-10301348-B2 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain | ADORA2A, ADORA3, ADORA2B | PI4KA 3311/4885PI4K2B 3941/4885PI4K2A 2856/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PI4KA 2834/4885PI4K2B 2839/4885PI4K2A 3014/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PI4KA 2674/4885PI4K2B 2552/4885PI4K2A 2966/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | PI4KA 1903/4885PI4K2B 2525/4885PI4K2A 2240/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | PI4KA 4490/4885PI4K2B 3867/4885PI4K2A 4444/4885 |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | PI4KA 1903/4885PI4K2B 2525/4885PI4K2A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.